Lexicon has initiated the phase-II clinical trial of LX1032, an oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is designed to reduce serotonin production in patients with metastatic carcinoid tumors.
LX1032 is being developed in a product development collaboration with Symphony Capital Partners and its co-investors.
The clinical trial is designed as a four-week, randomized, double-blind, placebo-controlled study, to evaluate the safety and tolerability of LX1032 and its effects on symptoms associated with carcinoid syndrome. The study would include up to 28 patients with carcinoid syndrome, who are symptomatic despite treatment with currently available therapy.
Philip Brown, Senior Vice President of clinical development at Lexicon, said: “This is an important study, designed to evaluate LX1032’s effect on the gastrointestinal symptoms experienced by patients with carcinoid syndrome who have become refractory to current treatment options. We are encouraged by the clinical results obtained to date in which LX1032 demonstrated potent reductions in serotonin production in healthy volunteers.”
Lexicon has three other drug candidates progressing through various stages of clinical development, including LX1031 for irritable bowel syndrome, LX2931 for rheumatoid arthritis, and LX4211 for diabetes, said the company.